Like this article?
Get your free daily medical news from Physician's First Watch.
Once-Yearly Zoledronic Acid Approved for Prevention of Fractures After Hip Fracture
Once-yearly zoledronic acid (Reclast) — an intravenous bisphosphonate used to treat osteoporosis — is now approved to prevent new fractures in patients who've had a hip fracture, the manufacturer has announced.
The drug's label was expanded based on a randomized study in which older adults given zoledronic acid after hip-fracture repair were significantly less likely to experience new vertebral or nonvertebral fractures, compared with those given a placebo infusion.
Side effects included fever and muscle pain, usually within 3 days of the infusion.
LINK(S):
Manufacturer's press release (Free)
Reclast prescribing information (Free PDF)
Physician's First Watch coverage of study showing benefits of zoledronic acid after hip fracture (Free)
Published in Physician's First Watch June 9, 2008
Your Remark:
To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.